George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Up 71%, Is Novavax Stock Still a Strong Buy?

The outbreak of a deadly respiratory virus caused Novavax's shares to take flight yesterday. Can the biotech's stock climb even higher, or is it time to take profits?

Is HEXO Stock a Buy?

The Canadian cannabis grower and distributor had a dreadful 2019 that sent its shares tumbling to levels that could be tempting for bargain hunters.